Compare ARK Genomic Revolution ETF (ARKG) vs Lennar Corporation (LEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Lennar Corporation — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Lennar Corporation trades at $84 (market cap $20.25B). The key difference: Lennar Corporation pays a 2.37% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Lennar Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | LEN | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $142.40 |
52-Week Low | $23.09 | $82.30 |
Market Cap | — | $20.25B |
Enterprise Value | — | $24.13B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Lennar Corporation (LEN) trades at $84.27, down 0.09% on the day, with the stock showing bearish technical signals despite trading near analyst consensus targets. The homebuilder faces margin pressure with net income declining from $4.6B in 2022 to $2.1B in 2025, though valuation metrics appear attractive with P/E of 13.2 and P/B of 0.9. Recent earnings have consistently missed expectations, with Q2 2026 results showing mixed performance amid challenging housing market conditions.
LEN presents a value opportunity with discounted valuations but faces significant headwinds from declining profitability and housing market volatility. The stock's outlook hinges on execution amid affordability pressures, with analyst consensus leaning bullish (46% buy ratings) but technical indicators suggesting caution. Key risks include ongoing margin compression and macroeconomic sensitivity to interest rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
